Abbott Laboratories, public healthcare company (NYSE ABT). Its Neuromodulation business includes Infinity and Liberta RC DBS and NeuroSphere programming. Robert B. Ford is parent chairman/CEO; this business is not an independent BCI startup.
Founded 1888
No investment rounds on record yet.
team@apexlogos.ai · 2 days ago
RELATED team@apexlogos.ai · 2 days ago
BCI research snapshot, reviewed 2026-10-06. Company identity: Abbott. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts.
Part 1/1
# Abbott Neuromodulation
Accessed: 2026-10-06. Research report for human review; no database changes made. Direct image URLs are extracted source assets, not invented filenames. Funding ledger is verified events found, not a complete lifetime total.
## Entity classification and pasted claims
**Neuromodulation is a business of Abbott, not an independently traded company.** Parent legal entity Abbott Laboratories, NYSE ABT, founded1888. Corporate headquarters is Abbott Park, Illinois; pasted Chicago is a metro simplification, not exact HQ. Robert B. Ford is parent chairman/CEO. Current [parent company](https://www.abbott.com/ ), [executive biography](https://www.abbott.com/en-us/about-abbott/leadership/executive-team/robert-ford ).
Infinity DBS is a real movement-disorder stimulation system. Current portfolio includes Liberta RC rechargeable DBS and NeuroSphere Virtual Clinic remote programming. [Official Liberta approval article](https://www.abbott.com/en-us/corpnewsroom/products-and-innovation/liberta-rc-dbs-system-is-fda-approved-3-things-to-know ); [FDA PMA record](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P140009S087 ). Active parent/business classification and ABT pass; do not import it as a standalone BCI venture. Device approval is indication-specific; [current official product advisories](https://www.neuromodulation.abbott/us/en/product-advisories.html ) show ongoing Infinity/Liberta safety updates, so “active” is not equivalent to no restrictions.
## Images and relevant team
Parent logo: https://www.abbott.com/content/dam/corp/abbottglobal/test-hub/Abbott-Logo.png — official HTML asset.
| Person | Role / currency | Profile and evidence | Direct pfp URL |
|---|---|---|---|
| Robert B. Ford | Current parent chairman and CEO | [Official individual profile](https://www.abbott.com/en-us/about-abbott/leadership/executive-team/robert-ford ) | https://www.abbott.com/content/dam/corp/abbottglobal/en-us/redesign/experts/Ford-Robert1-360x380.jpg (official picture/source asset) |
| Pedro Malha | VP Neuromodulation, last confirmed in 2023 official article; 2026 current role not independently confirmed | [Official business quote](https://www.abbott.com/en-us/corpnewsroom/products-and-innovation/innovating-for-people-a-135-year-legacy-continues ) | Unavailable: official article does not expose an attributable personal headshot. |
Wallace Calvin Abbott is the parent founder; he is not a founder of a separate modern Neuromodulation corporation. No verified comprehensive current division leadership roster was found on the consulted parent and neuromodulation pages. Keep Ford attached to parent and date Malha’s evidence rather than silently asserting current status.
## Investments / acquisitions / listing
No standalone venture round for “Abbott Neuromodulation” established. Public ABT is a parent stock listing. Abbott’s St. Jude Medical purchase was a completed acquisition (2017), not an equity funding round for this division. [2017 SEC acquisition accounting](https://www.sec.gov/Archives/edgar/data/1800/000104746918000856/R15.htm ) records USD23.6B consideration (USD13.6B cash, USD10B Abbott shares) and≈USD5.9B debt assumed/repaid/refinanced. This differs from headline USD25B agreement estimates and is not division funding. [Issuer completed notice](https://abbott.mediaroom.com/2017-01-04-Abbott-Completes-the-Acquisition-of-St-Jude-Medical ) dates completion January4 2017. Parent Treasury issues/IPO history lie outside a startup financing ledger. No quantitative division funding total should be imported.
## Review / import decision
No exact Abbott entity appeared in the queried adex snapshot. Review a parent `AbbottLaboratories` plus explicitly typed division/product relationships. Do not create a standalone company whose “CEO” is the parent CEO and whose investments are parent acquisitions. Headquarters, legal entity and leader separation are required; division roster and Malha currency remain unresolved. SHOW MORE
Robert B. FordChairman and CEO